Trends in cancer-targeted antibody-drug conjugates.

about

Ligand-targeted theranostic nanomedicines against cancer Conjugates of Small Molecule Drugs with Antibodies and Other Proteins.

P2860

Q35895637-3403DF0D-32F0-4E10-B2A0-D3B34531BA7B Q50977893-F444B778-91E7-48FF-89AF-BB251073E5C5

P2860

Trends in cancer-targeted antibody-drug conjugates.

Item

http://www.wikidata.org/entity/Q38162127

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Trends in cancer-targeted antibody-drug conjugates.

@en

type

Item

label

Trends in cancer-targeted antibody-drug conjugates.

@en

prefLabel

Trends in cancer-targeted antibody-drug conjugates.

@en

P1476

Trends in cancer-targeted antibody-drug conjugates

@en

P2093

Olivier Trédan

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Toward selection of internalizing antibodies from phage libraries.

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

Selecting and screening recombinant antibody libraries.

Mylotarg: antibody-targeted chemotherapy comes of age.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

P2888

s11523-013-0302-9

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-013-0302-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

F C Bidard

Olivier Trédan

P577

2013-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010218781

http://www.w3.org/2001/XMLSchema#string

P698

24221961

http://www.w3.org/2001/XMLSchema#string

Trends in cancer-targeted antibody-drug conjugates.

about

P2860

P2860

Trends in cancer-targeted antibody-drug conjugates.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698